1. Effects of Helicobacter pylori Treatment on Gastric Cancer Incidence and Mortality in Subgroups.
- Author
-
Wen-Qing Li, Jun-Ling Ma, Lian Zhang, Brown, Linda M., Ji-You Li, Lin Shen, Kai-Feng Pan, Wei-Dong Liu, Yuanreng Hu, Zhong-Xiang Han, Crystal-Mansour, Susan, Pee, David, Blot, William J., Fraumeni Jr, Joseph F., Wei-Cheng You, and Gail, Mitchell H.
- Subjects
TREATMENT of helicobacter pylori infections ,STOMACH cancer ,CANCER-related mortality ,METAPLASIA ,DYSPLASIA ,HISTOPATHOLOGY ,THERAPEUTICS - Abstract
Among 2258 Helicobacter pylori-seropositive subjects randomly assigned to receive one-time H. pylori treatment with amoxicillin-omeprazole or its placebo, we evaluated the 15-year effect of treatment on gastric cancer incidence and mortality in subgroups defined by age, baseline gastric histopathology, and post-treatment infection status. We used conditional logistic and Cox regressions for covariable adjustments in incidence and mortality analyses, respectively. Treatment was associated with a statistically significant decrease in gastric cancer incidence (odds ratio = 0.36; 95% confidence interval [Cl] = 0.17 to 0.79) and mortality (hazard ratio = 0.26; 95% Cl = 0.09 to 0.79) at ages 55 years and older and a statistically significant decrease in incidence among those with intestinal metaplasia or dysplasia at baseline (odds ratio = 0.56; 95% Cl = 0.34 to 0.91). Treatment benefits for incidence and mortality among those with and without post-treatment infection were similar. Thus H. pylori treatment can benefit older members and those with advanced baseline histopathology, and benefits are present even with post-treatment infection, suggesting treatment can benefit an entire population, not just the young or those with mild histopathology. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF